FDG-PET and tumour marker tests for the diagnosis of breast cancer

Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options

Volumn , Issue , 2008, Pages 189-200

  Bombardieri, Emilio ^a   Alessi, Alessandra ^a   Pallotti, Federica ^a   Serafini, Gianluca ^a   Mazzuca, Nicola ^b   Seregni, Ettore ^a   Crippa, Flavio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870993518     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-36781-9_15     Document Type: Chapter

References (70)

1. Adler LP, Bakale G (2001) Positron emission tomography imaging. In: Khalkali I, Maublant JC, Goldsmith SJ (eds) Nuclear oncology. Diagnosis and therapy. Lippincott Williams & Wilkins, Philadelphia 289-295
2. Agresti R, Crippa F, Gerali A et al (2004) Lymph node metastases detection by FDG-PET and sentinel node biopsy in breast cancer patients: comparison of these different approaches. ESSOI Congress
3. 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun 28:267-272
4. Avril N, Dose J, Janicke F et al (1996) Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14:1848-1857
5. Avril N, Scheidhauer K, Kuhun W (2000) Breast cancer. In: Helmut J, Wieler R, Coleman E (eds) PET in clinical oncology. Springer, New York, 355-372
6. Bast RC, Ravdin P, Hayes DF et al (2001) American Society of Clinical Oncology Tumor Markers Expert Panel. J Clin Oncol 19:1865-1878
7. Basuyau JP, Blanc-Vincent MP, Bidart JM et al (2003) Summary report of the standards, options and recommendations for the use of serum tumour markers on breast cancer: 2000. Br J Cancer 89:32-34
8. Benchimol S. Fuks A, Jothy S, Beauchemin N, Shirota K, Stanner C (1989) Carcinoembryonic antigen, a human tumor marker, functions as a intercellular adhesion molecule. Cell 57:327-334
9. Bender H, Palmedo H, Biersack HJ (1998) Breast imaging with positron emission tomography. In: Taillefer R, Khalkhali I, Waxman AD, Biersack HJ (eds) Radionu-clide imaging of the breast. Marcel Dekker, New York, 147-175
10. Berling B, Kolbinger F, Gruntert F et al (1990) Molecular cloning of a carcinoembryonic antigen (CEA)-gene family member expressed in leukocytes of chronic my-eloid leukaemia patients and bone marrow. Cancer Res 50:6534-6539
11. Bombardieri E (1998) Tumor markers. In: Masson (ed) Handbook of medical oncology. Parigi, Barcellona, Mes-sico, Milan, 145-159
12. Brem RF, Schoonians JM, Kieper DA et al (2002) High-resolution scintimammography: a pilot study. J Nucl Med 43:909-915
13. Chan DW, Beveridge RA, Muss H et al (1997) Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15:2322-2328
14. Cheung KL, Graves CRL, Robertson JFR (2000) Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26:91-102
15. Cody HS 3rd (2003) Sentinel lymph node biopsy for breast cancer: does anybody not need one? Ann Surg Oncol 10:1131-1132
16. 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 75:135-146
17. Delbeke D, Martin WH (2004) Metabolic imaging with FDG: a primer. Cancer J 10:201-213
18. Dose J, Bleckmann S, Bachmann S et al (2002) Comparison of fluorodeoxyglucose positron emission tomography and conventional diagnosis procedures for the detection of distant metastases in breast cancer patients. Nucl Med Commun 23:857-864
19. Duffy MJ (2001) Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 34:347-352
20. Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345-351
21. Gil-Rendo A, Zorzona G, Garcia-Velloso MJ, Regueira FM, Beorlegui C, Cervera M (2006) Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93:707-712
22. Gion M, Barioli P, Mione R et al (1995) Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting defi nitive assessment. Forza Operativa Na-zionale sul Carcinoma Mammario (FONCaM) Ann Oncol 6:31-35
23. Gion M, Boracchi P, Dittadi R et al (2002) Prognostic role of serum CA 15.3 in 362 node-negative breast cancer. An old player for a new game. Eur J Cancer 38:1181-1188
24. Gion M, Mione R, Bruscagni G (1993) Clinical use of tumor markers, current strategies for decision making. In: Ballesta A, Torre GC, Bombardieri E, Gion M, Molina R. Updating on tumor markers in tissues and in biological fluids. Minerva Medica, Torino, 179-202
25. Greco M, Crippa F, Agresti R et al (2001) Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 93:630-635
26. Hayes D, Sekine H, Ohao T et al (1985) Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 75:1671-1678
27. Hayes DF, Zurawski VR, Kufe DW (1986) Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 10:1542-1550
28. 18F-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 129:147-153
29. Kokko R, Holli K, Hakama M (2002) CA 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 38:1189-1193
30. Krag DN, Weaver DL, Alex JC et al (1993) Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma-probe. Surg Oncol 2:335-340
31. Liberman M, Sampalis F, Mulder DS et al (2003) Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature. Breast Cancer Res Treat 80:115-126
32. 18F-FDG PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 32:244-247
33. Lonneux M, Borbath I, Berlìere M, Kirkove C, Pauwels S (2000) The place of whole body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45-49
34. Lovrics PJ, Chen V, Coates G et al (2004) A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11:846-853
35. Molina R, Barak V, van Dalen A et al (2005) Tumor markers in breast cancer-European Group on Tumour Markers recommendations. Tumour Biol 26:281-293
36. Molina R, Jo J, Filella X et al (1999) C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 19:2551-2555
37. Nagle R (1988) Intermediate fi laments: a review of the basic biology. Am J Surg Pathol 12:4-16
38. Nakamura T, Kimura T, Umehara Y et al (2005) Periodic measurement of serum carcinombryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery. Surg Today 35:19-21
39. Ohta M, Tokuda Y, Suzuki Y et al (2001) Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22:875-879
40. Palmedo H, Bender H, Grunwald F et al (1997) Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxysobutylisoni-trile scintimammography in the detection of breast tumours. Eur J Nucl Med 24:1138-1145
41. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F et al (2001) Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2:229-234
42. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Isreal O (2006) The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 107:2545-2551
43. Ravaioli A, Pasini G, Polselli A et al (2002) Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 72:53-60
44. Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305-332
45. 99mTc-sestamibi. Am J Surg 185:544-549
46. 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 50:61-67
47. Scheidhauer K, Walter C, Seeman MD (2004) FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging 31:S170-S179
48. Schillaci O, Manni C, Danieli R et al (2005) Tc-99m sestamibi scintimammography with a hybrid SPECT/CT imaging system. Eur J Nucl Med Mol Imaging 32:S128
49. Schillaci O, Scopinaro F, Spanu A et al (2002) Detection of axillary lymph node metastases in breast cancer with Tc-99m tetrofosmin scintimammography. Int J Oncol 20:483-487
50. Schirrmeister H, Kuhn T, Guhlmann A et al (2001) Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351-358
51. Schoder H, Gonen M (2007) Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 48: S4-S18
52. Seregni E, Bombardieri E (1999) Tumor markers in oncology. In: Aktolun C, Tauxe WN (eds) Nuclear oncology. Springer, Berlin Heidelberg New York, 415-432
53. Seregni E, Coli A, Mazzuca N (2004) Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 31:S15-S22
54. 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 50:217-221
55. Siggelkow W, Rath W, Buell U, Zimny M (2004) FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging 31:S118-S124
56. Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W (2003) The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 23:1859-1867
57. Soletormos G, Nielsen D, Schioler V, Mouridsen H, Domber-nowsky P (2004) Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 40:481-486
58. Steiner PM, Roop DR (1988) Molecular and cellular biology of intermediate fi laments. Ann Rev Biochem 57:593-625
59. Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151-1159
60. Suarez M, Perez-Castejon MJ, Jimenez A, Domper M, Ruiz G, Montz R, Carreras JL (2002) Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46:113-121
61. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33:254-262
62. Trampal C, Maldonado A, Sancho Cuesta F et al (2000) Role of the positron emission tomography (PET) in suspected tumor recurrence when there are increased serum tumor markers. Rev Esp Med Nucl 19:279-287
63. Ugrinska A, Bombardieri E, Stokkel MP, Crippa F, Pauwels EK (2002) Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q J Nucl Med 46:88-104
64. Valenzuela P, Mateos S, Tello E, Lopez-Bueno MJ, Garrido N, Gaspar MJ (2003) The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 24:60-62
65. Veronesi U, De Cicco C, Galimberti V et al (2007) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18:473-478
66. Veronesi U., Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid AD in breast cancer with clinically negative lymph nodes. Lancet 349:1864-1867
67. Voogd AC, Nielsen M, Peterse JL et al (2001) Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19:1688-1697
68. 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphos-phonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128:325-328
69. Zangheri B, Messa C, Picchio M et al (2004) PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 31:S135-S142
70. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 30:15-19